All In Biotech

Drug Trial Radar · NCT05789082

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 320 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

320

Planned (sponsor's estimate)

Start

Jun 20, 2023

Primary completion

Jan 29, 2032

Study completion Jan 29, 2032

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Mar 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • DivarasibDrug

    Participants will receive divarasib orally (PO), QD on days 1-21 of each 21-day cycle.

  • PembrolizumabDrug

    Participants will receive a 200 mg IV infusion of pembrolizumab Q3W on Day 1 of each 21-day cycle.

  • CarboplatinDrug

    Participants will receive IV carboplatin Q3W for four 21-day cycles.

  • CisplatinDrug

    Participants will receive IV cisplatin Q3W for four 21-day cycles.

  • PemetrexedDrug

    Participants will receive IV pemetrexed Q3W.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Adverse Events (AEs)Time frame: Baseline until 60 days after the final dose of study treatment or until initiation of another anti-cancer therapy, whichever occurs first (up to approximately 5 years)

Locations

71 sites in 18 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California · Withdrawn

  • City of Hope - Seacliff

    Huntington Beach, California · Withdrawn

  • City of Hope at Irvine Lennar

    Irvine, California · Withdrawn

  • UCSD Moores Cancer Center

    La Jolla, California · Withdrawn

  • City of Hope - Long Beach Elm

    Long Beach, California · Withdrawn

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Florida Cancer Specialists - SOUTH - SCRI - PPDS

    Fort Myers, Florida · Recruiting

  • Florida Cancer Specialists - NORTH - SCRI - PPDS

    St. Petersburg, Florida · Recruiting

  • Florida Cancer Specialists - EAST - SCRI - PPDS

    West Palm Beach, Florida · Recruiting

  • NYU Langone Hospital - Long Island

    Mineola, New York · Recruiting

  • NYU Cancer Center

    New York, New York · Recruiting

  • Mount SInai Medical Center

    New York, New York · Recruiting

  • Montefiore Medical Center - Montefiore Medical Park

    The Bronx, New York · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Oncology & Hematology Associates of Southwest Virginia, Inc

    Blacksburg, Virginia · Recruiting

  • Virginia Oncology Associates

    Norfolk, Virginia · Recruiting

  • Hospital Britanico

    Buenos Aires, Argentina · Recruiting

  • Clinica Adventista Belgrano

    Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Centro Oncologico Riojano Integral (CORI)

    La Rioja, Argentina · Recruiting

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia · Completed

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Alfred Health

    Melbourne, Victoria, Australia · Recruiting

  • Cliniques Universitaires St-Luc

    Brussels, Belgium · Recruiting

  • Jessa Zkh (Campus Virga Jesse)

    Hasselt, Belgium · Recruiting

  • Clinique Ste-Elisabeth

    Namur, Belgium · Recruiting

  • AZ Delta (Campus Rumbeke)

    Roeselare, Belgium · Recruiting

  • Hospital de Cancer de Barretos

    Barretos, São Paulo, Brazil · Recruiting

  • Instituto do Cancer do Estado de Sao Paulo - ICESP

    São Paulo, São Paulo, Brazil · Recruiting

  • Ottawa Hospital Regional Cancer Centre

    Ottawa, Ontario, Canada · Recruiting

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada · Active not recruiting

  • Jewish General Hospital

    Montreal, Quebec, Canada · Recruiting

  • Hunan Cancer Hospital

    Changsha, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, China · Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, China · Recruiting

  • Rambam Medical Center

    Haifa, Israel · Recruiting

  • Rabin MC

    Petah Tikva, Israel · Recruiting

  • Tel Aviv Sourasky Medical Ctr

    Tel Aviv, Israel · Recruiting

  • Istituto Nazionale Tumori Fondazione G. Pascale

    Naples, Campania, Italy · Withdrawn

  • Policlinico Universitario Agostino Gemelli IRCCS

    Rome, Lazio, Italy · Active not recruiting

  • Irccs Istituto Nazionale Dei Tumori (Int)

    Milan, Lombardy, Italy · Recruiting

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.